{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit of the 95% CI could not be estimated due to the low number of participants being analyzed.","groupId":"OG000","lowerLimit":"0.3","upperLimit":"NA","value":"0.6"},{"groupId":"OG001","lowerLimit":"0.9","upperLimit":"13.9","value":"4.1"},{"comment":"Confidence interval could not be calculated as only one participant was analyzed","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"2.2"},{"groupId":"OG003","lowerLimit":"5.6","upperLimit":"13.9","value":"9.1"},{"groupId":"OG004","lowerLimit":"2.8","upperLimit":"5.4","value":"3.8"},{"groupId":"OG005","lowerLimit":"3.6","upperLimit":"20.2","value":"8.9"},{"groupId":"OG006","lowerLimit":"3.9","upperLimit":"9.5","value":"7.1"},{"groupId":"OG007","lowerLimit":"6.0","upperLimit":"18.0","value":"9.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"32"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"description":"Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered once daily (QD) oral dose of 2 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 2 mg QD"},{"description":"Participants were administered once daily oral dose of 4 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 4 mg QD"},{"description":"Participants were administered once daily oral dose of 8 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 8 mg QD"},{"description":"Participants were administered once daily oral dose of 16 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 16 mg QD"},{"description":"Participants were administered once daily oral dose of 30 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 30 mg QD"},{"description":"Participants were administered once daily oral dose of 60 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 60 mg QD"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants were administered once daily oral dose of 100 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 100 mg QD"}],"paramType":"MEDIAN","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.38 months of drug exposure","title":"Overall Survival-Part 1 QD","type":"SECONDARY","unitOfMeasure":"Months"}